NYSE - Nasdaq Real Time Price USD

Novartis AG (NVS)

98.35 +1.07 (+1.10%)
At close: 4:00 PM EDT
97.01 -1.34 (-1.36%)
After hours: 7:06 PM EDT
Loading Chart for NVS
DELL
  • Previous Close 97.28
  • Open 98.50
  • Bid 97.00 x 1000
  • Ask 100.00 x 1100
  • Day's Range 97.40 - 98.55
  • 52 Week Range 92.19 - 108.78
  • Volume 2,221,706
  • Avg. Volume 1,578,035
  • Market Cap (intraday) 201.138B
  • Beta (5Y Monthly) 0.47
  • PE Ratio (TTM) 23.99
  • EPS (TTM) 4.10
  • Earnings Date --
  • Forward Dividend & Yield 3.78 (3.88%)
  • Ex-Dividend Date Mar 7, 2024
  • 1y Target Est 113.07

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

www.novartis.com

76,057

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NVS

Related Videos: NVS

Performance Overview: NVS

Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NVS
1.13%
MSCI WORLD
4.86%

1-Year Return

NVS
1.80%
MSCI WORLD
0.00%

3-Year Return

NVS
25.76%
MSCI WORLD
12.80%

5-Year Return

NVS
57.64%
MSCI WORLD
52.84%

Compare To: NVS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NVS

Valuation Measures

Annual
As of 4/23/2024
  • Market Cap

    198.95B

  • Enterprise Value

    211.34B

  • Trailing P/E

    23.73

  • Forward P/E

    13.77

  • PEG Ratio (5yr expected)

    5.30

  • Price/Sales (ttm)

    4.36

  • Price/Book (mrq)

    4.25

  • Enterprise Value/Revenue

    4.53

  • Enterprise Value/EBITDA

    11.58

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    31.94%

  • Return on Assets (ttm)

    8.65%

  • Return on Equity (ttm)

    19.83%

  • Revenue (ttm)

    47.73B

  • Net Income Avi to Common (ttm)

    9.11B

  • Diluted EPS (ttm)

    4.10

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.65B

  • Total Debt/Equity (mrq)

    68.63%

  • Levered Free Cash Flow (ttm)

    13.33B

Research Analysis: NVS

Analyst Price Targets

101.00
113.07 Average
98.35 Current
129.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: NVS

Fair Value

98.35 Current
 

Dividend Score

0 Low
NVS
Sector Avg.
100 High
 

Hiring Score

0 Low
NVS
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
NVS
Sector Avg.
100 High
 

Research Reports: NVS

  • Analyst Report: Novartis AG

    Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

    Rating
    Price Target
     
  • Analyst Report: Novartis AG

    Novartis is a pharmaceutical company based in Switzerland. Its portfolio is focused primarily on the areas of Immunology, Neuroscience, Oncology, Cardiovascular, Renal, and Metabolic therapies. The company employs more than 78,000 people and its medicines reach more than 280 million people worldwide.

    Rating
    Price Target
     
  • Market Update: NVS, BYD, CVX, DE, ITGR, CBOE, FTV

    Stocks are trading lower on Tuesday morning on some weaker-than-expected economic data as well as growing concerns that AI-related stocks are overbought at this juncture. Specifically, the Conference Board's Leading Economic Index slipped 0.4% in January and was lower than the expected 0.3% drop. The index was down 3.0% over the past six months -- a narrower decline than the preceding six-month period, which fell by 4.1%. Still, with six of the 10 index components being positive over the past six-month period, the index no longer is signaling a recession ahead. Turning to stocks, shares of Nvidia (NVDA) are down today, with the company reporting earnings tomorrow after market close. Despite expectations for positive earnings results, the selloff indicates many investors may be concerned that the shares are due for a pullback following an impressive run this year (which saw shares rise over 50% to an all-time high set last week). Shares of other tech companies which also saw strong gains related to AI prospects are trading lower on overvaluation concerns, including Arm Holdings (ARM), Advanced Micro Devices (AMD), and Super Micro Computer (SMCI).

     
  • Analyst Report: Novartis AG

    Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

    Rating
    Price Target
     

People Also Watch